• Clinical Trials - Lymphoma

    Study Objective Contact
    A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study Of RAD001 Adjuvant Therapy In Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-Line Rituximab Chemotherapy [LCID Study Number: 2010-002] This study is being done to see if giving RAD001 can reduce the chance of relapse when it is given to patients with diffuse large B-cell lymphoma that is in complete remission. Rad001 is currently not approved by the FDA for use in this situation therefore, this treatment is considered experimental. Principal Investigator(s):
    Tarun Kewalramani, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Deborah J. Gannon,
    Nancy M. Campbell, RN.